MedinCell, a French biotech company has presented positive results from a clinical trial validating the safety of continuous administration of ivermectin. There is increasing evidence of ivermectin’s prophylactic effects on COVID-19. The inexpensive drug, which is primarily used as an antiparasitic therapy, has been used widely off-label in parts of the world, and the evidence of its effects continues to accrue. MedinCell has shared phase 1 data on the continuous daily administration of ivermectin. The results are an early step in a program that could lead to the use of a long-acting injectable formulation of the molecule.
The data suggest that the drug can be safely administered for one month at doses up to 75 µg/kg. No significant side effects were observed in the first cohorts (daily doses of 50 μg/kg, 75 μ respectively) studied successively. Continuous administration over 1 month to healthy volunteers in the first two cohorts of the study confirms Ivermectin’s safety up to a dose of 75 µg/kg. The in vivo tests suggest that the injectable formulation in the form of the prefilled syringe is stable for up to 2 years at room temperature. MedinCell is extending the release of ivermectin using its BEPO technology.
The technology is based on copolymers and a biocompatible solvent that is formulated with the active ingredient. After administration, the components trap the active ingredient in a depot that then gradually degrades by hydrolysis to release the ingredient. The candidate is designed to form small subcutaneous depots of ivermectin to enable the ongoing release of the drug.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here
Ref link: https://www.businesswire.com/news/home/20201217006031/en/Covid-19-MedinCell-Presents-Positive-First-Results-From-the-Clinical-Trial-Aiming-at-Validating-the-Safety-of-Continuous-Administration-of-Ivermectin